Skip to main content

Advertisement

Table 3 Baseline model parameters (based on [2, 4])

From: The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000–2014)

Parameter Hydrocele average estimate Lymphedema average estimate Source
Acute Disease
 Percentage of clinical patients who experience ADL episodes per year 70 % 95 % [8, 1017]
 Frequency of ADL episodes for clinical patients (in absence of MDA) 2 per year 4 per year [8, 1017]
 Average duration of an ADL episode 4 days 4 days [8, 1017]
 Reduction in the frequency of ADL episodes by MDA 50 % 50 % [33, 36, 37]
Chronic Disease
 Percentage in different clinical disease states 62.5 % 37.5 % [7]
 Percentage of chronic disease alleviated by MDA 10 % 15 % [20, 3035]
  1. Due to the lack of region-specific data, a standard rate or proportion was utilized for each GPELF country. ADL acute adenolymphangitis, MDA mass drug administration